Cas:64714-79-0 ethyl 3-oxo-5-phenylmethoxypentanoate manufacturer & supplier

Chemical Name:ethyl 3-oxo-5-phenylmethoxypentanoate

CAS.NO:64714-79-0

Synonyms:Aethyl-5-benzyloxy-3-oxo-pentanoat;ethyl 5-benzyloxy-3-oxopentanoate;5-benzyloxy-3-oxo-pentanoic acid ethyl ester;ethyl 5-benzyloxy-3-oxovalerate

Molecular Formula:C₁₄H₁₈O₄

Molecular Weight:250.29000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:52.60000

Exact Mass:250.12100

LogP:2.11560

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Aethyl-5-benzyloxy-3-oxo-pentanoat chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ethyl 5-benzyloxy-3-oxovalerate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Aethyl-5-benzyloxy-3-oxo-pentanoat Use and application,ethyl 5-benzyloxy-3-oxopentanoate technical grade,usp/ep/jp grade.

Related News: Britons being brought from Wuhan to the UK are being placed in quarantine at Arrowe Park Hospital in the Wirral, northwest England, Raab said. ethyl 3-oxo-5-phenylmethoxypentanoate manufacturer New Zealand on Sunday became the latest country to impose restrictions on travelers from mainland China, saying it would deny entry to visitors departing from or transiting through the mainland for two weeks starting on Monday. ethyl 3-oxo-5-phenylmethoxypentanoate supplier Multinational drugmakers usually cut the price of drugs when they go off-patent and face competition from generic versions, but such price drops were slow to happen in China, partially because many local drugmakers were unable to develop high-quality generic drugs to compete with off-patent branded drugs. ethyl 3-oxo-5-phenylmethoxypentanoate vendor US citizens who’ve been in other parts of mainland China in the last 14 days will undergo screening at US ports of entry and up to 14 days of self-monitoring. ethyl 3-oxo-5-phenylmethoxypentanoate factory A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.